Search

Displaying results 2481 - 2490 of 10000 in total
  1. Drug

    Acetrizoic acid

    go.drugbank.com/drugs/DB09347
    ApprovedWithdrawn

    [A32135] It was first synthesized by Wallingford in 1953[A32136] and it was filled in the FDA by the Johnson & Johnson subsidiary, Cilag Chemie AG, on February 8th, 1978. … [L1704] Acetrizoic acid presents, in the FDA records, a category of drug substance with an inactive status.[L1703]

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Lebrikizumab

    go.drugbank.com/drugs/DB11914
    ApprovedInvestigational

    years and older with a body weight of at least 40 kg. … [A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12

  3. Drug

    Quinupristin

    go.drugbank.com/drugs/DB01369
    Approved

    The combination of the two components acts synergistically and is more effective in vitro than each component alone. … Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.

  4. Drug

    Aliskiren

    go.drugbank.com/drugs/DB09026
    ApprovedInvestigational

    [A203624] It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. … [L14018] Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.[A203624]

    Categories: Agents Acting on the Renin-Angiotensin System
  5. Drug

    Protein S human

    go.drugbank.com/drugs/DB13149
    ApprovedInvestigational

    It serves as a negative feedback mechanism in the coagulation cascade.

    Mixtures: COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET
  6. Drug

    Influenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10793
    ApprovedInvestigational

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Mixtures: INFLUVAC TETRA, SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE 0.5 ML, Fluarix Quadrivalent 2019/2020
  7. Drug

    Vezocolmitide

    go.drugbank.com/drugs/DB21751
    Investigational

    Vezocolmitide is under investigation in clinical trial NCT06178679 (Safety and Efficacy of ST-100 (Vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed With Dry Eye Disease

    Synonyms: ST-100
  8. Target

    Protein RecA

    go.drugbank.com/bio_entities/BE0001235
    TargetMycobacterium smegmatis (strain ATCC 700084 / mc(2)155)

    Required for homologous recombination (HR) and the bypass of mutagenic DNA lesions (double strand breaks, DSB) by the SOS response. Can catalyze the hydrolysis of ATP in the presence of single-stranded DNA, the ATP-dependent uptake of si...

    Polypeptides: Protein RecA
  9. Target

    Proteasome activator complex subunit 1

    go.drugbank.com/bio_entities/BE0008976
    TargetHumans

    The PA28 activator complex enhances the generation of class I binding peptides by altering the cleavage pattern of the proteasome

    Polypeptides: Proteasome activator complex subunit 1Synonyms: 11S regulator complex subunit alpha
  10. Target

    MHC class II protein complex

    go.drugbank.com/bio_entities/BE0011001
    TargetHumans